Free Trial
NASDAQ:PRPH

ProPhase Labs (PRPH) Stock Price, News & Analysis

ProPhase Labs logo
$0.75 0.00 (0.00%)
(As of 11/26/2024 ET)

About ProPhase Labs Stock (NASDAQ:PRPH)

Key Stats

Today's Range
$0.71
$0.75
50-Day Range
$0.74
$2.63
52-Week Range
$0.66
$7.48
Volume
92,682 shs
Average Volume
61,177 shs
Market Capitalization
$17.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Buy

Company Overview

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

ProPhase Labs Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
63rd Percentile Overall Score

PRPH MarketRank™: 

ProPhase Labs scored higher than 63% of companies evaluated by MarketBeat, and ranked 402nd out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ProPhase Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ProPhase Labs has received no research coverage in the past 90 days.

  • Read more about ProPhase Labs' stock forecast and price target.
  • Earnings Growth

    Earnings for ProPhase Labs are expected to grow in the coming year, from ($1.23) to ($0.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ProPhase Labs is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ProPhase Labs is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ProPhase Labs has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.65% of the outstanding shares of ProPhase Labs have been sold short.
  • Short Interest Ratio / Days to Cover

    ProPhase Labs has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ProPhase Labs has recently decreased by 25.23%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    ProPhase Labs does not currently pay a dividend.

  • Dividend Growth

    ProPhase Labs does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.65% of the outstanding shares of ProPhase Labs have been sold short.
  • Short Interest Ratio / Days to Cover

    ProPhase Labs has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ProPhase Labs has recently decreased by 25.23%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    2 people have added ProPhase Labs to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ProPhase Labs insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.70% of the stock of ProPhase Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 9.45% of the stock of ProPhase Labs is held by institutions.

  • Read more about ProPhase Labs' insider trading history.
Receive PRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter.

PRPH Stock News Headlines

This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
ProPhase Labs: Strategic Moves for Future Growth
ProPhase Labs Announces Closing of Public Offering of Common Stock
See More Headlines

PRPH Stock Analysis - Frequently Asked Questions

ProPhase Labs' stock was trading at $4.52 at the start of the year. Since then, PRPH stock has decreased by 83.4% and is now trading at $0.7490.
View the best growth stocks for 2024 here
.

ProPhase Labs, Inc. (NASDAQ:PRPH) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.21. The company had revenue of $3.63 million for the quarter, compared to analysts' expectations of $9.86 million. ProPhase Labs had a negative trailing twelve-month return on equity of 62.92% and a negative net margin of 217.64%.

Top institutional investors of ProPhase Labs include HighTower Advisors LLC (0.75%) and Geode Capital Management LLC (0.67%).
View institutional ownership trends
.

Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that ProPhase Labs investors own include Meta Platforms (META), Pfizer (PFE), Palantir Technologies (PLTR), Valero Energy (VLO), CymaBay Therapeutics (CBAY), Catalyst Pharmaceuticals (CPRX) and Energy Transfer (ET).

Company Calendar

Last Earnings
5/09/2024
Today
11/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PRPH
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+1,368.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-16,780,000.00
Net Margins
-217.64%
Pretax Margin
-298.21%

Debt

Sales & Book Value

Annual Sales
$12.75 million
Book Value
$2.74 per share

Miscellaneous

Free Float
18,932,000
Market Cap
$17.88 million
Optionable
Optionable
Beta
-0.10

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:PRPH) was last updated on 11/26/2024 by MarketBeat.com Staff
From Our Partners